Zdrowie i gospodarka · 18.02.1998
Draft Guidance for Industry: Clinical Development Programs for Drugs, Devices, and Biological Products Intended for the Treatment of Osteoarthritis (OA); Availability
The Food and Drug Administration (FDA) is announcing the availability of, and requesting comment on a draft guidance for industry entitled ``Clinical Development Programs for Drugs, Devices, and Biological Products Intended for the Treatment of Osteoarthritis (OA).'' The purpose of the draft guidance and the discussion questions appended to the draft guidance is to stimulate discussion and seek input about designing clinical programs for the development of drugs, devices, and biological products intended for the treatment of OA. The draft guidance and appended questions will be the topics of discussion at the Arthritis Advisory Committee meeting to be held on February 20, 1998.